Surgical Results after Neoadjuvant Nivolumab and Platinum-based Chemotherapy for Resectable Lung Cancer. A Multicentre European Real Clinical Practice Analysis

作者：Alessandro Brunelli, Alessio Vincenzo Mariolo, Clemens Aigner, David Gómez de Antonio, Marcelo F. Jiménez, Hanan Hemead, Ross J. S. Hoffman, Joshil Lodhia, Marco Nardini, Giovanni Mattioni, Katharina Sinn, Mir Alireza Hoda, Nuria Novoa, Guillermo Rodriguez Davila, María Teresa Gómez-Hernández, Cristina Rivas-Duarte, Pooja Bhatnagar, K. Clarke, Carles Escriu, Omar Fakih, K. Franks, Kheira Bouaziz, Virginia Calvo, María Sereno, Mariano Provencio, Nicolas Girard, Michael Shackcloth · 发表于：European Journal of Cardio-Thoracic Surgery · 年份：2025 · DOI：10.1093/ejcts/ezaf343 · 被引用次数：3 · 研究领域：Lung Cancer Diagnosis and Treatment、Cancer Immunotherapy and Biomarkers、Lung Cancer Treatments and Mutations

OBJECTIVES: To evaluate the real clinical practice surgical outcomes following neoadjuvant nivolumab in combination with chemotherapy in a multicentre European cohort of patients. METHODS: Retrospective analysis on consecutive patients treated in 6 tertiary referral hospitals in Europe with neoadjuvant chemotherapy and immunotherapy (nivolumab) for stage II-IIIB non-small cell lung cancer (March 2023-December 2024). Surgical and pathological outcomes were assessed. RESULTS: A total of 340 patients started neoadjuvant treatment. Three hundred seventeen patients (93.2%) were able to proceed to surgery. Forty-seven percent of patients had surgery more than 6 weeks after completion of the last neoadjuvant cycle. Two hundred eight operations (66%) were started using a minimally invasive approach with a conversion rate of 18%. The most frequent resection was lobectomy in 86% of patients. Ninety-day postoperative mortality rate was 2.5%. The pathologic complete response occurred in 95 patients (30% of the surgical patients), major pathologic response in 167 patients (52.7% of the surgical patients). The incidence of pathologic complete response (P = .78) and major pathologic response (P = .26) were similar in patients with clinical stage II and III. Pathologic complete response rate was higher in patients with programmed death-ligand 1 (PD-L1) ≥ 50% compared to those with PD-L1 < 50% (37.5% vs 27.2%, P = .082). A higher pathologic complete response (39% vs 23%, P = .004) and major p...